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TO THE EDITOR
Alopecia areata (AA) is a chronically
relapsing skin disorder characterized
by a sudden loss of hair. Because the
perception of patients may differ
significantly from those of their
health-care providers, quality of life
(Qol) appears to be a more relevant
criterion to assess the severity of this
disease than clinical evaluation such as
AA extension. To our knowledge, only
one Turkish study investigated the
impact of AA on Qol using short form
36 (SF36), indicating lower Qol levels
compared with sex-matched indivi-
duals (Gulec et al., 2004). In this study,
Qol was assessed using a generic
instrument. Because only three dimen-
sions were affected and results may be
linked to the specific culture, a con-
firmation was needed. We used an
approach combining generic and spe-
cific measures to assess the impact of
AA on French patients’ Qol, to compare
Qol levels with those observed in the
general population and in other derma-
tological conditions, and finally to
determine the impact of clinical char-
acteristics and sociodemographic fac-
tors on Qol.
Subjects were aged over 16 years,
presenting with a minimum of 8 weeks
AA history, having given informed
consent to participate, and having the
French language as their native lan-
guage. Sociodemographic data and
characteristics of the disease (duration
and course, treatments in the recent
period, affected surfaces on the scalp
and other areas involved) were re-
corded. The severity of each AA was
reported using visual analogical scales
(0–10) by reference to (i) all the AA
cases seen in daily practice; (ii) all
cases of all skin disorders. Three self-
administered questionnaires were used
to assess Qol: the generic and world-
wide-used SF36 (Leplege et al., 1998,
2001; Coste, 2001), and two ‘‘chronic
skin disorders’’-specific Qol instru-
ments with French validated available
versions, the VQ-Dermato (Grob
et al., 1999, 2009) and the Skindex
(Chren et al., 1996, 1997; Leplege
et al., 2003). To better figure out the
level of QoL in AA, we compared
AA scores with those available in
literature related to the French popula-
tion: (1) rare dermatological diseases
including hidradenitis suppurativa
(Wolkenstein et al., 2007) and neurofi-
bromatosis type 1 (Wolkenstein et al.,
2001); (2) chronic/frequent dermatolo-
gical diseases including psoriasis,
chronic idiopathic urticaria, and atopic
dermatitis (Grob et al., 2005); (3)
general population: French age- and
sex-matched controls (Leplege et al.,
2001). This study was conducted in
adherence to the Helsinki guidelines.
Institutional approval was not required
for experiments. After having given
their inform consent, 60 patients were
included (39 women and 21 men);
their mean age was 40.1 years (SD
15.2) and median AA duration was
6 years (2 months to 60 years). Course
of the disease was stable in 25 subjects
and unstable in 35. The median of
the scalp surface involved was 77%.
The median of severity score was 6.5
(range 4.0–9.0) by reference to the AA
patients and 3.5 (range 2.0–6.0) by
reference to the patients presenting
any skin disorder.
Mental health and vitality were the
most altered SF36 dimensions, whereas
physical functioning, role physical and
body pain were the least ones. Regard-
ing VQ-Dermato, daily life, leisure
activity, and physical discomfort were
the least altered dimensions. For Skin-
dex, emotions dimension was the most
affected and symptoms the least one.
Compared with the general population
and with patients suffering from other
dermatological conditions (Table 1), AA
patients presented significantly altered
Qol for almost all the SF36 dimensions.
For VQ-Dermato, AA patients reported
(i) significantly better (mood state,
leisure activity, daily life, and physical
discomfort) or worse scores (self-per-
ception) than psoriasis, chronic idio-
pathic urticaria, and atopic dermatitis
patients; (ii) being less bothered to
treatment-induced restrictions than
psoriasis, but more than chronic idio-Abbreviations: AA, alopecia areata; Qol, quality of life; SF36, short form 36
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Table 1. Quality-of-life indicative comparisons between AA patients and other dermatological conditions, and
French age- and sex-matched controls1
AA, N=60 HS, N=61 P NF1, N=128 P PSO, N=408 P CU, N=367 P AD, N=386 P Controls P
SF362
Physical functioning 88.2±22.5 71.3±27.4 o0.001 76.8±26.4 0.004 90.3±7.0 0.506
Role—physical 73.3±35.0 43.6±39.0 o0.001 72.8±39.1 0.932 87.0±6.7 0.006
Bodily pain 77.2±20.7 44.5±24.4 o0.001 65.3±29.6 0.005 77.9±6.3 0.865
General health 64.3±22.7 43.3±22.4 o0.001 58.4±23.0 0.101 72.2±5.3 0.011
Vitality 54.5±20.4 40.4±20.4 o0.001 49.7±21.3 0.146 62.4±3.2 0.005
Social functioning 58.9±29.5 52.5±25.8 0.206 70.4±25.7 0.007 84.1±3.5o0.001
Role—emotional 64.1±39.1 42.9±42.0 0.004 69.4±39.4 0.390 86.3±5.1o0.001
Mental health 49.3±20.4 43.0±18.4 0.077 56.4±22.0 0.036 69.7±2.7o0.001
VQ-Dermato3
Self-perception 51,4±26.2 52.2±26.7 0.868 37.4±24.7 o0.001 23.8±21.8 o0.001 34.2±24.6 o0.001
Daily life 13.9±17.7 46.9±28.7 o0.001 19.3±19.4 0.145 36.2±20.4 o0.001 35.5±21.3 o0.001
Mood state 34.2±24.1 37.9±26.4 0.422 49.3±25.2 o0.001 50.3±25.5 o0.001 50.1±25.5 o0.001
Social functioning 31.8±25.1 47.6±29.7 0.002 31.3±23.7 0.880 27.5±22.9 0.184 34.1±23.5 0.485
Leisure activity 23.9±28.4 52.1±31.3 o0.001 47.2±29.3 o0.001 36.7±28.1 o0.001 46.7±27.9 o0.001
Treatment restrictions 30.3±30.2 35.8±34.0 0.349 38.6±26.0 0.024 17.0±20.7 o0.001 32.5±26.4 0.556
Physical discomfort 25.0±26.9 66.1±26.5 o0.001 44.4±28.2 o0.001 61.4±23.7 o0.001 69.8±21.3 o0.001
Skindex4
Emotions 48.9±27.8 59.2±23.4 0.029 31.6±26.7 o0.001
Symptoms 18.3±19.7 52.2±22.3 o0.001 21.4±19.7 0.315
Functioning 28.0±24.6 48.8±25.5 o0.001 22.3±23.3 0.126
Abbreviations: AA, alopecia areata; AD, atopic dermatitis; CU, chronic urticaria; HS, hidradenitis suppurativa; NF1, neurofibromatosis type 1; PSO,
psoriasis; SF36, short form 36.
1From Leplege et al., (2001), Wolkenstein et al., (2001), Grob et al., (2005), and Wolkenstein et al., (2007).
2SF36, 36 items, eight dimensions (range (0–100), 0 lowest and 100 highest level of Qol; Leplege et al., 1998; Coste, 2001; Leplege et al., 2001).
3VQ-Dermato, 28 items, seven domains and one overall score (range (0–100), 0 highest and 100 lowest level of Qol; Grob et al., 1999, 2009).
4Skindex, 29 items, three domains (range (0–100), 0 highest and 100 lowest level of Qol; Chren et al., 1996, 1997; Leplege et al., 2003).
Bold values Po0.05.
Table 2. Associations between VQ-Dermato dimension scores and global score, and sociodemographic/clinical
characteristics in 60 alopecia areata (AA) patients
Self-










Men 42.28±21.54 10.24±15.04 32.74±21.28 27.40±18.00 13.10±17.98 30.47±26.99 19.05±25.19 25.88±15.04
Women 53.66±28.47 16.05±18.94 35.02±25.78 34.29±28.23 30.07±31.51 30.15±32.00 28.38±27.58 32.30±21.83
P 0.196 0.341 0.839 0.499 0.042 0.694 0.161 0.406
Educational level1
o12 Years 48.58±28.48 13.75±18.57 27.08±23.99 26.09±25.18 21.21±29.06 26.14±29.61 24.46±27.30 27.02±21.57
X12 Years 53.18±24.89 14.02±17.36 38.54±23.41 35.51±24.74 25.58±28.31 33.48±30.82 25.36±27.03 32.40±18.69
P 0.409 0.670 0.059 0.103 0.429 0.380 0.934 0.149
Table 2 continued on the following page
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Table 2. Continued
Self-










Single 59.16±22.61 14.87±17.88 36.61±25.72 38.65±28.62 30.95±32.07 35.16±38.52 26.25±30.05 34.71±24.22
Couple 47.09±27.33 13.43±17.82 32.83±23.36 28.07±22.49 19.93±25.74 27.94±25.76 24.34±25.49 27.88±17.33
P 0.109 0.583 0.614 0.141 0.210 0.815 0.952 0.457
Occupational status1
Not working 43.63±26.97 8.51±12.41 28.08±23.79 29.62±25.49 23.02±28.25 27.63±31.62 21.59±27.87 27.43±21.63
Working 56.00±24.97 17.06±19.63 37.67±23.87 33.15±25.16 24.44±28.90 31.85±29.73 27.08±26.47 31.66±19.09
P 0.075 0.119 0.159 0.603 0.973 0.554 0.403 0.371
Disease course1,3
Stable 51.37±30.26 15.95±20.00 38.28±26.41 35.27±27.75 29.34±29.88 40.48±35.33 27.60±31.27 34.88±23.31
Unstable 51.40±23.26 12.42±15.96 31.31±22.25 29.31±23.11 20.10±27.15 22.84±23.87 23.16±23.66 27.07±17.04
P 0.701 0.630 0.340 0.474 0.138 0.093 0.792 0.174
Scalp surface involved1
o80% 47.35±24.20 11.96±14.59 29.22±22.37 29.91±23.69 15.48±22.88 20.97±22.22 25.35±27.14 25.34±16.81
X80% 57.70±28.47 17.01±21.76 42.33±25.07 34.86±27.49 36.78±31.60 45.39±35.65 24.43±27.13 38.20±22.43
P 0.065 0.693 0.064 0.512 0.006 0.016 0.887 0.023
Extrascalp involvement1
No 48.82±24.25 11.68±14.84 30.34±21.39 29.53±22.80 17.32±24.46 23.11±24.43 24.68±26.98 26.08±16.15
Yes 56.40±29.67 18.38±22.13 42.11±27.78 36.33±29.24 36.46±31.73 44.12±35.94 25.66±27.47 38.32±24.39
P 0.178 0.405 0.113 0.484 0.016 0.043 0.890 0.049
Alopecia universalis1
No 50.55±25.30 14.86±17.46 32.82±22.97 31.16±24.16 21.85±27.48 29.38±30.16 26.63±27.21 30.30±19.16
Yes 54.35±30.10 10.35±18.89 38.94±28.08 34.23±29.22 31.09±31.58 33.75±31.76 18.75±25.84 29.65±23.64
P 0.458 0.260 0.487 0.840 0.309 0.656 0.327 0.970
Age2 0.099 0.134 0.236 0.149 0.173 0.120 0.059 0.294
P 0.456 0.322 0.075 0.260 0.195 0.406 0.661 0.042
Disease duration2 0.118 0.090 0.073 0.157 0.084 0.095 0.145 0.039
P 0.376 0.511 0.589 0.239 0.536 0.518 0.281 0.793
Severity 12,4 0.247 0.027 0.319 0.180 0.359 0.396 0.057 0.348
P 0.059 0.844 0.015 0.173 0.006 0.004 0.673 0.015
Severity 22,5 0.216 0.056 0.334 0.187 0.383 0.377 0.038 0.390
P 0.101 0.679 0.010 0.156 0.003 0.007 0.777 0.006
1Mean ± SD, P: P-value Mann–Whitney test.
2Spearman’s correlation coefficient, P: P-value Spearman’s test.
3Course of the disease was defined as ‘‘unstable’’ if there was alternation of worsening and improvement phases in the last 2 years, and ‘‘stable’’ otherwise.
4Severity 1: visual analog scale by reference to the cases of AA seen in daily practice; 0 ‘‘patient among the least affected’’ and 100 ‘‘patient among the most
affected’’.
5Severity 2: visual analog scale by reference to the cases of all skin disorders seen in daily practice; 0 ‘‘patient among the least affected’’ and 100 ‘‘patient
among the most affected’’.
Bold values: Po0.05.
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pathic urticaria patients. AA patients
reported significantly better Qol than
did hidradenitis suppurativa patients,
except for social functioning and
mental health dimensions of SF36
and self-perception, mood state, and
treatment restriction dimensions of
VQ-Dermato.
Skindex and SF36 were not statisti-
cally linked to sociodemographic and
clinical parameters (data not shown).
Only the VQ-Dermato global score
indicated a significantly better Qol
in older subjects (Table 2). Disease
severity, extrascalp involvement, and
scalp surface involved were related
with altered VQ-dermato dimensions
(Table 2).
Our results show that (1) Qol is
impaired in AA, the most influenced
domains being self-perception,
such as in the Gulec et al (2004) study,
and also mental health and social life. It
may be because of the special impor-
tance of hair in appearance (Cash,
1999; Firooz et al., 2005); (2) social
life is impaired in AA at the same level
as in psoriasis, atopic dermatitis, and
chronic idiopathic urticaria. On the
dimensions dealing with mental health
and social life, AA also compares very
well with hidradenitis suppurativa, one
of the rare skin disorders with the
highest impact on most dimensions of
Qol (Wolkenstein et al., 2007). Simi-
larly, social life and mental comfort of
patients seem to be more affected in AA
than in neurofibromatosis type 1;
(3) sociodemographic parameters did
not impact Qol, except for leisure
activities, with women appearing to
be more affected; (4) clinical severity
of AA appears to be poorly linked to
Qol, even when assessed with a sensi-
tive dermatology-specific Qol tool (VQ-
Dermato). Furthermore, the dimension
of self-perception, which seems to be
particularly involved in AA, is not
significantly linked to the clinical se-
verity of the disorder.
Some limitations must be men-
tioned. The sample size did not allow
a multivariate approach, and moderate
associations were possibly missed ow-
ing to low power. We were unable to
confirm the impact of anxiety or de-
pression on Qol (Gulec et al., 2004)
because these parameters were not
collected. One must be cautious while
generalizing the study findings to minor
cases seen in everyday care because
our hospital-based series of AA was
probably not representative of commu-
nity cases. Although we did not system-
atically search for other health disorders
in our patients, none of them declared
to have one.
Although AA is a perfectly benign
disorder, this work confirms the initial
hypothesis that AA seriously impairs
Qol, mainly by altering self-perception
and self-esteem, both of which interfere
with social life. From a practical point
of view, these results can (i) help
doctors to realize that they probably
strongly underestimate the severity
of AA and encourage them to give
patients the treatments and the psycho-
logical help they require; (ii) help
patients by showing that their suffering
is understood by others; (iii) help
health-care decision-makers to promote
therapeutic trials in this orphan
disorder.
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